A Literature Overview of Secondary Peritonitis Due to Carbapenem-Resistant Enterobacterales (CRE) in Intensive Care Unit (ICU) Patients

被引:3
作者
Di Franco, Sveva [1 ]
Alfieri, Aniello [2 ]
Fiore, Marco [1 ]
Fittipaldi, Ciro [3 ]
Pota, Vincenzo [1 ]
Coppolino, Francesco [1 ]
Sansone, Pasquale [1 ]
Pace, Maria Caterina [1 ]
Passavanti, Maria Beatrice [1 ]
机构
[1] Univ Campania Luigi Vanvitelli, Dept Women Child & Gen & Specialized Surg, Piazza Miraglia 2, I-80138 Naples, Italy
[2] AORN Antonio Cardarelli, Dept Postoperat Intens Care Unit & Hyperbar Oxyge, Viale Antonio Cardarelli 9, I-80131 Naples, Italy
[3] Unit Crit Care Hosp Osped Pellegrini, Via Portamedina Pignasecca 41, I-80134 Naples, Italy
来源
ANTIBIOTICS-BASEL | 2022年 / 11卷 / 10期
关键词
beta-lactam/beta-lactamase inhibitors; carbapenemase; combination therapy; critically ill patients; intra-abdominal infections; Enterobacterales; postoperative peritonitis; precision medicine; secondary peritonitis; SEPTIC SHOCK; INFECTIONS; EPIDEMIOLOGY; SUSCEPTIBILITY; MANAGEMENT; PLAZOMICIN; OPTIONS; SEPSIS;
D O I
10.3390/antibiotics11101347
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
This comprehensive review of the recently published literature offers an overview of a very topical and complex healthcare problem: secondary peritonitis from multidrug-resistant pathogens, especially carbapenem-resistant Enterobacterales (CRE). Spontaneous secondary peritonitis and postsurgical secondary peritonitis are among the major causes of community- and healthcare-acquired sepsis, respectively. A large number of patients enter ICUs with a diagnosis of secondary peritonitis, and a high number of them reveal infection by CRE, P. aeruginosa or A. baumannii. For this reason, we conceived the idea to create a synthetic report on this topic including updated epidemiology data, a description of CRE resistance patterns, current strategies of antimicrobial treatment, and future perspectives. From this update it is clear that antimicrobial stewardship and precision medicine are becoming essential to fight the emergence of antimicrobial resistance and that even if there are new drugs effective against CRE causing secondary peritonitis, these drugs have to be used carefully especially in empirical therapy.
引用
收藏
页数:17
相关论文
共 48 条
[1]   Applications of Machine Learning to the Problem of Antimicrobial Resistance: an Emerging Model for Translational Research [J].
Anahtar, Melis N. ;
Yang, Jason H. ;
Kanjilal, Sanjat .
JOURNAL OF CLINICAL MICROBIOLOGY, 2021, 59 (07)
[2]   Acquired Class D beta-Lactamases [J].
Antunes, Nuno T. ;
Fisher, Jed F. .
ANTIBIOTICS-BASEL, 2014, 3 (03) :398-434
[3]   Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial [J].
Bassetti, Matteo ;
Echols, Roger ;
Matsunaga, Yuko ;
Ariyasu, Mari ;
Doi, Yohei ;
Ferrer, Ricard ;
Lodise, Thomas P. ;
Naas, Thierry ;
Niki, Yoshihito ;
Paterson, David L. ;
Portsmouth, Simon ;
Torre-Cisneros, Julian ;
Toyoizumi, Kiichiro ;
Wunderink, Richard G. ;
Nagata, Tsutae D. .
LANCET INFECTIOUS DISEASES, 2021, 21 (02) :226-240
[4]   Phenotypic Screening of Carbapenemases and Associated β-Lactamases in Carbapenem-Resistant Enterobacteriaceae [J].
Birgy, Andre ;
Bidet, Philippe ;
Genel, Nathalie ;
Doit, Catherine ;
Decre, Dominique ;
Arlet, Guillaume ;
Bingen, Edouard .
JOURNAL OF CLINICAL MICROBIOLOGY, 2012, 50 (04) :1295-1302
[5]   The international sepsis forum consensus conference on definitions of infection in the intensive care unit [J].
Calandra, T ;
Cohen, J .
CRITICAL CARE MEDICINE, 2005, 33 (07) :1538-1548
[6]  
Davies Sally C, 2021, Future Healthc J, V8, pe251, DOI 10.7861/fhj.2021-0087
[7]  
De Waele J, 2014, BMC INFECT DIS, V14, DOI [10.1186/1471-2334-14-420, 10.1186/1471-2334-14-193]
[8]  
Emeraud C, 2019, ANTIMICROB AGENTS CH, V63, DOI [10.1128/AAC.00010-19, 10.1128/aac.00010-19]
[9]   Antibiotic Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae: Systematic Evaluation of the Available Evidence [J].
Falagas, Matthew E. ;
Lourida, Panagiota ;
Poulikakos, Panagiotis ;
Rafailidis, Petros I. ;
Tansarli, Giannoula S. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (02) :654-663
[10]  
Falagas ME, 2011, FUTURE MICROBIOL, V6, P653, DOI [10.2217/FMB.11.49, 10.2217/fmb.11.49]